BRIEF—Pandion Therapeutics raises $58 million and appoints new chief executive

East Coast, USA-based Pandion Therapeutics has raised $58 million in a series A funding round, co-led by Polaris Partners, Versant Ventures and Roche Venture Fund.

The firm says the money will be used to advance its initial drug programs for autoimmune and inflammatory diseases toward the clinic, as well as to continue building the company’s technology platform and pipeline.

The firm also appointed Anthony Coyle as chief executive officer and Jo Viney as chief scientific officer.

Dr Coyle was previously a senior vice president at Pfizer and vice president and global head of inflammation biologics at MedImmune.

Dr Viney was previously senior vice president of drug discovery and VP of immunology research at Biogen and formerly of Amgen.

Pandion’s initial areas of drug development include inflammatory bowel disease, autoimmune liver disease, kidney diseases, type 1 diabetes, and autoimmune skin conditions.